Literature DB >> 30908154

Clinical and Molecular Features of 5 European Multigenerational Families With Moyamoya Angiopathy.

Lou Grangeon1, Stéphanie Guey1, Jan Claudius Schwitalla2, Françoise Bergametti1, Minh Arnould1, Michaelle Corpechot3, Jessica Hadjadj3, Florence Riant3, Chaker Aloui1, Severine Drunat4, Dominique Vidaud5, Elisabeth Tournier-Lasserve1,3, Markus Kraemer2,6.   

Abstract

Background and Purpose Moyamoya angiopathy (MMA) is a rare cerebral vasculopathy outside of Asia. In Japanese patients, a vast majority of patients carry the founder p.R4810K variant in the RNF213 gene, and familial cases are around 10%. In European patients, data about familial occurrence are limited. The aim of this study was to characterize the clinical and molecular features of several European families with a parent-to-child transmission of MMA. Methods Out of 126 MMA probands referred, we identified 113 sporadic probands and 13 familial probands. Segregation analysis showed a vertical parent-to-child pattern of inheritance in the families of 5 of these probands. All 5 families were of German or Dutch ancestry. We investigated the clinical features of affected members and used whole-exome sequencing to screen RNF213 and 13 genes involved in Mendelian MMA and to identify genes recurrently mutated in these families. Results Twelve affected MMA patients were identified, including 9 females and 3 males. Age at clinical onset ranged from 11 to 65 years. In 3 of 5 families, associated livedo racemosa was found. We did not detect any deleterious variants in the 13 known MMA genes. RNF213 rare missense variants predicted to be pathogenic were detected in all affected members of 2 of these families, as well as 2 candidate variants of the PALD1 gene. Conclusions Nonsyndromic MMA was identified in 5 European families, including 2 to 3 clinically affected cases segregating with a parent-to-child pattern of inheritance in each family. Molecular screening detected rare deleterious variants within RNF213 and PALD1 in all affected members of 2 of these 5 families, as well as in some clinically unaffected members. Altogether these data raise the difficult and, to date unanswered, question of the medical indication of presymptomatic screening.

Entities:  

Keywords:  Moyamoya disease; child; family; parent; whole exome sequencing

Mesh:

Substances:

Year:  2019        PMID: 30908154     DOI: 10.1161/STROKEAHA.118.023972

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  13 in total

Review 1.  Thalassemia and Moyamoya syndrome: unfurling an intriguing association.

Authors:  Shambaditya Das; Souvik Dubey; Mrinal Acharya; Subhankar Chatterjee; Durjoy Lahiri; Goutam Das; Biman Kanti Ray; Markus Kraemer
Journal:  J Neurol       Date:  2019-08-17       Impact factor: 4.849

2.  Moyamoya angiopathy in PHACE syndrome not associated with RNF213 variants.

Authors:  Jeffrie Hadisurya; Stephanie Guey; Lou Grangeon; Dagmar Wieczorek; Michaelle Corpechot; Jan Claudius Schwitalla; Markus Kraemer
Journal:  Childs Nerv Syst       Date:  2019-04-29       Impact factor: 1.475

3.  Cardiac manifestations in a western moyamoya disease population: a single-center descriptive study and review.

Authors:  Anthony S Larson; Luis Savastano; James Klaas; Giuseppe Lanzino
Journal:  Neurosurg Rev       Date:  2020-06-07       Impact factor: 3.042

4.  Clinical presentation of Moyamoya angiopathy in Europeans: experiences from Germany with 200 patients.

Authors:  Markus Kraemer; Jan Claudius Schwitalla; Frank Diesner; Orhan Aktas; Hans-Peter Hartung; Peter Berlit
Journal:  J Neurol       Date:  2019-03-13       Impact factor: 4.849

5.  Cerebral arteriopathy associated with heterozygous variants in the casitas B-lineage lymphoma gene.

Authors:  Ying Hong; Annette Keylock; Barbara Jensen; Thomas S Jacques; Olumide Ogunbiyi; Ebun Omoyinmi; Dawn Saunders; Andrew A Mallick; Madeleine Tooley; Ruth Newbury-Ecob; Julia Rankin; Hywel J Williams; Vijeya Ganesan; Paul A Brogan; Despina Eleftheriou
Journal:  Neurol Genet       Date:  2020-06-10

6.  Paladin is a phosphoinositide phosphatase regulating endosomal VEGFR2 signalling and angiogenesis.

Authors:  Anja Nitzsche; Riikka Pietilä; Dominic T Love; Chiara Testini; Takeshi Ninchoji; Ross O Smith; Elisabet Ekvärn; Jimmy Larsson; Francis P Roche; Isabel Egaña; Suvi Jauhiainen; Philipp Berger; Lena Claesson-Welsh; Mats Hellström
Journal:  EMBO Rep       Date:  2020-12-28       Impact factor: 8.807

Review 7.  Moyamoya Disease and Spectrums of RNF213 Vasculopathy.

Authors:  Oh Young Bang; Jong-Won Chung; Dong Hee Kim; Hong-Hee Won; Je Young Yeon; Chang-Seok Ki; Hyung Jin Shin; Jong-Soo Kim; Seung Chyul Hong; Duk-Kyung Kim; Akio Koizumi
Journal:  Transl Stroke Res       Date:  2019-10-24       Impact factor: 6.829

8.  PHACTR1 is associated with disease progression in Chinese Moyamoya disease.

Authors:  Yongbo Yang; Jian Wang; Qun Liang; Yi Wang; Xinhua Chen; Qingrong Zhang; Shijie Na; Yi Liu; Ting Yan; Chunhua Hang; Yichao Zhu
Journal:  PeerJ       Date:  2020-05-05       Impact factor: 2.984

Review 9.  A critical appraisal of bypass surgery in moyamoya disease.

Authors:  Michael Moussouttas; Igor Rybinnik
Journal:  Ther Adv Neurol Disord       Date:  2020-05-26       Impact factor: 6.570

10.  The angiographic presentation of European Moyamoya angiopathy.

Authors:  Sara Pilgram-Pastor; René Chapot; Markus Kraemer
Journal:  J Neurol       Date:  2021-07-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.